Posts tagged Joseph Pantginis


Capricor Therapeutics Inc (CAPR) Investors Throw Bullish Parade After H.C. Wainwright Boosts Price Target

Analyst spotlights a compelling path forward for DMD program and looks to key catalysts in fourth quarter.

H.C. Wainwright Sees 230% Upside Potential For Sophiris Bio Inc (SPHS) As Prostate Cancer Drug Enters Phase 2b Trial

Analyst Joseph Pantginis of H.C. Wainwright is optimistic regarding the pace of Sophiris Bio Inc’s (NASDAQ:SPHS) Phase 2b study …

Rodman and Renshaw Sings the Praises of Capricor Therapeutics, Inc. (CAPR); Here’s Why

On Tuesday, Capricor Therapeutics, Inc. (NASDAQ:CAPR) was granted FDA Rare Pediatric Disease Designation for CAP-1002, the …

Rodman & Renshaw Encouraged on Rexahn Pharmaceuticals, Inc. (RNN) Following ASCO Update

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) offered a key glimpse into its advanced muscle invasive bladder cancer …

Sophiris Bio Inc (SPHS): Phase 2b Trial One Step a Way to Take Off

Drug maker Sophiris Bio Inc (NASDAQ:SPHS) released its earnings report for the first quarter of 2017 …

Cytokinetics, Inc.’s (CYTK) CK-107 Could Benefit from SMA Demand

H.C. Wainwright analyst Joseph Pantginis is out today with a research note on Cytokinetics, Inc. …

This Analyst Sees Over 200% Upside For Rexahn Pharmaceuticals, Inc. (RNN) Shares

In a research report issued Thursday, H.C. Wainwright analyst Joseph Pantginis assumed coverage on shares of …

Sophiris Bio Inc (SPHS): Prostate Cancer Drug Continues To Impress

Following Sophiris Bio Inc’s (NASDAQ:SPHS) fourth-quarter and 2016 financial results released yesterday coupled with last …

Rodman & Renshaw Initiates Buy on Sophiris Bio Inc (SPHS), Sees 113% Upside for the Stock

Sophiris Bio Inc (NASDAQ:SPHS) shares are rising almost 17% on back of Rodman & Renshaw …